Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | NT5E | P21589 | 1/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.62 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.62 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.60 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.60 |
| ▸ | DPP4 | P27487 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.60 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.60 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.60 |
| ▸ | GAPDH | P04406 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | STAT6 | P42226 | 1/20 | 0.60 |
| ▸ | PI4KA | P42356 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16555404 | 1.00 | LMNA (0.62) | LMNANT5EHIF1AADORA2AADORA3 | |
| SCHEMBL6663083 | 0.89 | LMNA (0.62) | LMNANT5EHIF1AADORA2AADORA3 | |
| SCHEMBL2014081 | 0.89 | LMNA (0.62) | LMNANT5EHIF1AADORA2AADORA3 | |
| SCHEMBL3970946 | 0.89 | LMNA (0.62) | LMNANT5EHIF1AADORA2AADORA3 | |
| SCHEMBL899617 | 0.89 | LMNA (0.62) | LMNANT5EHIF1AADORA2AADORA3 | |
| SCHEMBL11481461 | 0.88 | LMNA (0.61) | LMNANT5EHIF1AADORA2AADORA3 | |
| SCHEMBL2424283 | 0.88 | LMNA (0.64) | LMNANT5EHIF1AADORA2AADORA3 | |
| SCHEMBL62505 | 0.88 | CYP2C19 (0.62) | LMNANT5EHIF1AADORA2AADORA3 | |
| SCHEMBL7535713 | 0.88 | HPGD (0.62) | LMNANT5EHIF1AADORA2AADORA3 | |
| SCHEMBL14931005 | 0.88 | CYP2C19 (0.62) | LMNANT5EHIF1AADORA2AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024192269-A2 | ENZYMATIC METHODS AND COMPOSITIONS FOR POLYMERIZATION OF PHOSPHORAMIDATE AND THIOPHOSPHORAMIDATE-LINKED DNA | THE GENERAL HOSPITAL CORPORATION (US) | 2024-09-19 | — | — | WO | claimed |
| CN-111527205-B | Novel method for synthesizing polynucleotides using diverse libraries of oligonucleotides | 里本生物实验室有限责任公司 | 2024-12-17 | — | — | CN | disclosed |
| CN-119110732-A | Gene editing for improving joint function | 奥泽生物疗法公司 | 2024-12-10 | — | — | CN | disclosed |
| WO-2024192269-A2 | ENZYMATIC METHODS AND COMPOSITIONS FOR POLYMERIZATION OF PHOSPHORAMIDATE AND THIOPHOSPHORAMIDATE-LINKED DNA | THE GENERAL HOSPITAL CORPORATION (US) | 2024-09-19 | — | — | WO | disclosed |
| EP-4399294-A1 | GUIDE RNAS WITH CHEMICAL MODIFICATION FOR PRIME EDITING | Agilent Technologies, Inc. (US) | 2024-07-17 | — | — | EP | disclosed |
| US-12037335-B2 | Substituted purines as TLR7 agonists | Primmune Therapeutics, Inc. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240116974-A1 | TLR7 AGONISTS | Primmune Therapeutics, Inc. | 2024-04-11 | — | — | US | disclosed |
| CN-117769598-A | Polynucleotide and pharmaceutical composition | 协和麒麟株式会社 | 2024-03-26 | — | — | CN | disclosed |
| WO-2023135265-A1 | MOLECULES TARGETING VIRAL RNA AND/OR VIRAL RNA-PROTEIN COMPLEXES FOR USE IN THE TREATMENT OF VIRAL INFECTIONS, IN PARTICULAR COVID-19 | Johann Wolfgang Goethe-Universität Frankfurt am Main (DE) | 2023-07-20 | — | — | WO | disclosed |
| EP-4212633-A1 | MOLECULES TARGETING VIRAL RNA AND/OR VIRAL RNA-PROTEIN COMPLEXES FOR USE IN THE TREATMENT OF VIRAL INFECTIONS, IN PARTICULAR COVID-19 | Johann-Wolfgang-Goethe-Universität Frankfurt am Main (DE) | 2023-07-19 | — | — | EP | disclosed |
| CN-112533607-A | TLR7 agonists | 普利缪尼治疗学股份有限公司 | 2021-03-19 | — | — | CN | disclosed |
| US-20210071317-A1 | COMBINATORIAL DERIVATIVES OF RNA OLIGONUCLEOTIDES | FARBER BORIS (US) | 2021-03-11 | — | — | US | disclosed |
| WO-2020237262-A1 | COMPOSITIONS AND METHODS RELATED TO TETHERED KETHOXAL DERIVATIVES | THE UNIVERSITY OF CHICAGO (US) | 2020-11-26 | — | — | WO | disclosed |
| WO-2020186187-A1 | METHODS FOR TREATING BLADDER AND URETHRA DYSFUNCTION AND DISEASE | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2020-09-17 | — | — | WO | disclosed |
| US-10729711-B2 | Methods for treatment using small molecule potassium-sparing diuretics and natriuretics | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2020-08-04 | — | — | US | disclosed |
| US-20190192544-A1 | METHODS FOR TREATMENT USING SMALL MOLECULE POTASSIUM-SPARING DIURETICS AND NATRIURETICS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2019-06-27 | — | — | US | disclosed |
| WO-2018198084-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS WITH TRICYCLIC NUCLEOBASES | LUPIN LIMITED (IN) | 2018-11-01 | — | — | WO | disclosed |
| EP-1986699-A2 | RNA INTERFERENCE AGENTS FOR THERAPEUTIC USE | University of Massachusetts (US) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007092182-A2 | RNA INTERFERENCE AGENTS FOR THERAPEUTIC USE | UNIVERSITY OF MASSACHUSETTS (US) | 2007-08-16 | — | — | WO | disclosed |
| EP-0699763-B1 | Nucleic acid sequence encoding trypsin-like enzyme and process for producing the enzyme | TEIJIN LTD (JP) | 1998-09-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116974-A1 | TLR7 AGONISTS | TLR7, TLR1, TLR9 | LMNA 2244/4885NT5E 1404/4885HIF1A 1103/4885 |
| US-10729711-B2 | Methods for treatment using small molecule potassium-sparing diuretics and natriuretics | PNP, GMPS, SLC5A1 | LMNA 538/4885NT5E 510/4885HIF1A 2919/4885 |
| US-12037335-B2 | Substituted purines as TLR7 agonists | TLR7, TLR9, TLR1 | LMNA 2179/4885NT5E 133/4885HIF1A 1403/4885 |
| US-20190192544-A1 | METHODS FOR TREATMENT USING SMALL MOLECULE POTASSIUM-SPARING DIURETICS AND NATRIURETICS | PNP, GMPS, SLC5A1 | LMNA 538/4885NT5E 510/4885HIF1A 2919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.